Monday was quite the day for biotech companies developing the next generation of obesity drugs. One of them, Structure ...

A recent Bloomberg Intelligence study found that buyside European equity traders want lighter regulation, more retail flow ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Binance, the world's largest crypto exchange, has reportedly secured three crucial financial licenses in Abu Dhabi's Global ...

US stocks fell on Monday as Wall Street awaited the Federal Reserve's final policy meeting of the year, while the deal drama ...

Bitcoin (CRYPTO: BTC) has bounced off recent lows but continues to trade in a structurally fragile environment, defined by ...

Gold Royalty has transitioned to recurring cash flow, with two consecutive quarters of positive operational cash flow and ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron, that just showed positive results from a Phase 2 trial.

Structure Therapeutics said on Monday that its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study.

Investing.com -- Structure Therapeutics Inc. (NASDAQ:GPCR) stock fell 4.1% in after-hours trading Monday following the announcement of a proposed $500 million public offering, giving back some of its ...

Bitcoin dominance is less about tribalism but more about more about where liquidity is willing to sit, and how participants ...

Kolkata's historic New Market, known as SS Hogg Market, is set to receive significant structural reinforcements to enhance ...